Darolutamide (Nubeqa) for Prostate Cancer

Date: December 16, 2019 Issue #:  1587Summary:  The FDA has approved darolutamide (Nubeqa– Bayer), an androgen receptor inhibitor, for oral treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC). Darolutamide is the third androgen receptor inhibitor to be approved for this indication; apalutamide(Erleada) and enzalutamide(Xtandi), which are also approved for use in patients with metastatic castration-resistant prostate cancer (mCRPC), were approved earlier.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: apalutamide darolutamide enzalutamide Erleada Nubeqa Prostate cancer Xtandi Source Type: research